Interim Report - January to September

Financial Highlights

• Revenue for the the first nine months of 2009 was SEK 19.0 (19.8) million
• Net loss for the period amounted to SEK –19.0 (-74.9) million
• Earnings per share was SEK –0.42 (-2.50)
• Cash flow from current operations was SEK –31.4 (-58.9) million
• SEK 36.4m raised in additional financing of which 20.2m in cash

Key Corporate Highlights

• A collaboration agreement has been signed with Biovitrum AB with the aim of developing new targeted therapeutics for inflammation and autoimmune diseases. This is in line with Affibody’s new strategy, aiming to generate profitable corporate partnerships across the life science sector based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM and designed to allow Affibody to reach its key corporate objective of sustainable profitability in the next two years.
• During the period, Affibody obtained the third and final approval required to commence a Phase I study in Germany with its lead molecular imaging agent, ABY-025, which is based on a highly specific Affibody® molecule that binds the breast cancer marker HER2.
• Affibody’s proprietary albumin binding technology, AlbumodTM, has gained interest from several companies searching for a relevant drug development technology.
• Affibody has obtained approval to commence an exploratory clinical study regarding bladder cancer in Uppsala.
• Half-life extension of ten times has been demonstrated in vivo by applying the AlbumodTM platform to G-CSF (more information can be found at http://www.affibody.se/en/Product-Portfolio/The_Albumin_Binding_Technology/Results/).

David Bejker CEO, said: “Affibody has during the first nine months of 2009 continued to deliver on the plan that was launched late last year. The first results from our internal AlbumodTM project have been generated according to plan and we expect to continue to generate interesting results from this program.”